Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
124.23
Dollar change
+4.46
Percentage change
3.72
%
Index- P/E45.99 EPS (ttm)2.70 Insider Own0.00% Shs Outstand3.38B Perf Week0.63%
Market Cap420.32B Forward P/E30.81 EPS next Y4.03 Insider Trans- Shs Float3.38B Perf Month8.27%
Income12.14B PEG16.42 EPS next Q0.78 Inst Own9.15% Short Float0.14% Perf Quarter21.79%
Sales33.70B P/S12.47 EPS this Y23.86% Inst Trans-2.71% Short Ratio1.04 Perf Half Y32.11%
Book/sh4.67 P/B26.62 EPS next Y19.95% ROA29.90% Short Interest4.67M Perf Year73.92%
Cash/sh1.32 P/C93.83 EPS next 5Y2.80% ROE87.44% 52W Range67.66 - 124.86 Perf YTD20.09%
Dividend Est.1.65 (1.33%) P/FCF34.86 EPS past 5Y16.48% ROI64.47% 52W High-0.51% Beta0.41
Dividend TTM2.06 (1.66%) Quick Ratio0.64 Sales past 5Y14.25% Gross Margin84.60% 52W Low83.61% ATR (14)2.64
Dividend Ex-DateAug 18, 2023 Current Ratio0.82 EPS Y/Y TTM56.16% Oper. Margin44.12% RSI (14)63.54 Volatility1.48% 1.76%
Employees63370 Debt/Eq0.25 Sales Y/Y TTM34.77% Profit Margin36.04% Recom2.03 Target Price119.73
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q71.63% Payout36.04% Rel Volume1.21 Prev Close119.77
Sales Surprise4.87% EPS Surprise6.77% Sales Q/Q44.01% EarningsJan 31 BMO Avg Volume4.49M Price124.23
SMA203.07% SMA5011.40% SMA20030.10% Trades Volume5,431,887 Change3.72%
Date Action Analyst Rating Change Price Target Change
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Oct-02-23Initiated Argus Buy $110
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Mar-01-24 06:15PM
04:06PM
01:45PM
11:35AM
01:59AM
02:32PM Loading…
Feb-29-24 02:32PM
02:21PM
09:00AM
08:28AM
06:42AM
Feb-28-24 10:07PM
05:37PM
04:56PM
10:00AM
09:50AM
07:54PM Loading…
Feb-27-24 07:54PM
06:01PM
10:53AM
10:04AM
07:54AM
07:32AM
Feb-26-24 03:45PM
01:52PM
06:02AM
05:04AM
Feb-24-24 07:10AM
Feb-23-24 12:44PM
Feb-22-24 09:21AM
07:00AM
01:00AM
10:00AM Loading…
Feb-21-24 10:00AM
09:45AM
09:03AM
Feb-20-24 01:58PM
06:55AM
Feb-19-24 09:29AM
Feb-18-24 09:30AM
Feb-17-24 01:29PM
Feb-16-24 01:35PM
01:27PM
Feb-15-24 11:35AM
11:05AM
Feb-14-24 04:43PM
11:48AM
10:23AM
08:30AM
06:59AM
02:59AM
Feb-13-24 05:50AM
Feb-12-24 11:22AM
09:30AM
09:15AM
07:13AM
05:06AM
05:03AM
12:50AM
12:47AM
Feb-11-24 01:06PM
12:25PM
10:15AM
Feb-10-24 11:40AM
09:53AM
08:30AM
06:49AM
01:47AM
Feb-09-24 10:47AM
10:17AM
09:13AM
08:14AM
Feb-08-24 04:56PM
10:00AM
09:55AM
08:23AM
06:48AM
06:37AM
06:15AM
04:53AM
Feb-07-24 03:22PM
12:55PM
12:23PM
11:53AM
06:53AM
Feb-06-24 05:23PM
04:37PM
02:48PM
01:43PM
10:25AM
08:37AM
02:49AM
02:20AM
Feb-05-24 06:25PM
06:07PM
04:35PM
02:03PM
01:46PM
01:21PM
12:31PM
12:27PM
10:57AM
10:35AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.